WEI HU to Drug Resistance, Neoplasm
This is a "connection" page, showing publications WEI HU has written about Drug Resistance, Neoplasm.
Connection Strength
0.197
-
Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 02; 105(19):1485-95.
Score: 0.041
-
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 2011 Apr 15; 117(8):1661-9.
Score: 0.034
-
Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. Am J Obstet Gynecol. 2009 Feb; 200(2):177.e1-9.
Score: 0.030
-
Diammine dicarboxylic acid platinum enhances cytotoxicity in platinum-resistant ovarian cancer cells through induction of apoptosis and S-phase cell arrest. Pharm Res. 2008 Oct; 25(10):2272-82.
Score: 0.029
-
Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer. J Cancer Res Clin Oncol. 2004 Jul; 130(7):423-8.
Score: 0.022
-
Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res. 2003 Mar; 9(3):1161-70.
Score: 0.020
-
Targeted therapies in gynecologic cancers. Curr Cancer Drug Targets. 2006 Jun; 6(4):333-63.
Score: 0.006
-
Targeted therapy for epithelial ovarian cancer: current status and future prospects. Int J Gynecol Cancer. 2003 Nov-Dec; 13(6):701-34.
Score: 0.005
-
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan. Cancer Chemother Pharmacol. 2004 Jan; 53(1):1-7.
Score: 0.005
-
Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2003 Sep; 90(3):552-9.
Score: 0.005